Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metronomic Cyclophosphamide in Advanced NPC
NCT02794077Phase 2Completed
- Sponsor
- The University of Hong Kong
- Start
- Jan 2008
- Primary completion
- Dec 2015
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of cyclophosphamide in nasopharyngeal carcinoma (NPC), sponsored by The University of Hong Kong. Primary endpoint: Progression-Free Survival at 12 months. Started Jan 2008; status: completed.
02
Drugs
cyclophosphamide
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT02794077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02794077.